US Broker Ratings

Viking Therapeutics (VKTX): Analyst Ratings Indicate a Potential Upside of Over 194%

Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, is garnering significant attention from investors with its promising drug pipeline and substantial potential upside. With a market capitalization of $3.59..

Arcellx, Inc. (ACLX) Stock Analysis: Unpacking a 63.90% Potential Upside in the Biotech Sector

Arcellx, Inc. (NASDAQ: ACLX), a promising player in the biotechnology sector, has caught the attention of investors with its robust pipeline of immunotherapies targeting cancer and other incurable diseases. As..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Potential Upside with Innovative Rare Disorder Treatments

PTC Therapeutics, Inc. (PTCT) stands out in the biotechnology sector with its focus on developing and commercializing treatments for rare disorders. Headquartered in Warren, New Jersey, PTC Therapeutics is making..

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 37.5% Potential Upside in Biotech

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a prominent player in the biotechnology sector, presents a compelling case for investors seeking exposure to the high-growth healthcare industry. Specializing in rare neuroendocrine diseases,..

Oscar Health, Inc. (OSCR) Stock Analysis: Navigating Through a Volatile Market with a Strategic Outlook

Oscar Health, Inc. (NYSE: OSCR) is carving out a unique space in the healthcare sector, offering innovative health plans and technological platforms aimed at transforming the industry. With its current..

Nuvalent, Inc. (NUVL): Investor Outlook with a 33% Potential Upside

Nuvalent, Inc. (NASDAQ: NUVL) has emerged as a notable player in the biotechnology sector, focusing on innovative cancer therapies. As a clinical-stage biopharmaceutical company, Nuvalent is dedicated to developing targeted..

Cytokinetics, Incorporated (CYTK) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector

Cytokinetics, Incorporated (NASDAQ: CYTK), a prominent player in the biotechnology industry, has been catching the eye of investors with a compelling potential upside of 41.06%. This late-stage biopharmaceutical company is..

Sarepta Therapeutics (SRPT) Stock Analysis: Navigating a Challenging Biotech Landscape with a Potential Upside

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a prominent player in the biotechnology sector, primarily focusing on revolutionary treatments for rare diseases. Specializing in RNA-targeted therapeutics and gene therapies, the company..

Vaxcyte, Inc. (PCVX) Stock Analysis: Strong Analyst Consensus and Nearly 94% Upside Potential

Vaxcyte, Inc. (NASDAQ: PCVX), a promising player in the biotechnology sector, is capturing investor attention with its ambitious pipeline of innovative vaccines aimed at combating bacterial infectious diseases. With a..

Avidity Biosciences, Inc. (RNA) Stock Analysis: A Biotech Powerhouse with 434% Revenue Growth and Promising Clinical Trials

Avidity Biosciences, Inc. (NASDAQ: RNA) stands as a promising player in the biotechnology sector, captivating investor interest with its revolutionary approach to RNA therapeutics. Notably, the company has achieved an..

Merit Medical Systems, Inc. (MMSI) Stock Analysis: Exploring a 27% Upside Potential

Merit Medical Systems, Inc. (NASDAQ: MMSI) is a noteworthy player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $4.84 billion, the..

RadNet, Inc. (RDNT) Stock Analysis: A Healthcare Gem with a 25% Upside Potential

RadNet, Inc. (NASDAQ: RDNT), a leader in the healthcare diagnostics and research sector, offers a compelling opportunity for investors seeking growth in the medical imaging space. With a market capitalization..

Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring the 3.39% Potential Upside in Biotech Innovation

For investors with an eye on the biotechnology sector, Akero Therapeutics, Inc. (NASDAQ: AKRO) stands out as a compelling prospect. With its focus on tackling serious metabolic diseases, Akero is..

Bruker Corporation (BRKR) Stock Analysis: Navigating a 7.43% Potential Upside Amidst Industry Challenges

Bruker Corporation (NASDAQ: BRKR), a prominent player in the healthcare sector specializing in medical devices, presents a fascinating investment opportunity. With a market capitalization of $7.65 billion, Bruker is a..

Universal Health Services, Inc. (UHS) Stock Analysis: Exploring a 22% Potential Upside for Investors

Universal Health Services, Inc. (NYSE: UHS), a cornerstone in the healthcare sector, presents an intriguing opportunity for investors looking to capitalize on the burgeoning medical care facilities industry. With a..

Revolution Medicines, Inc. (RVMD) Stock Analysis: Exploring Growth Potentials with Robust Buy Ratings

Revolution Medicines, Inc. (RVMD), a key player in the biotechnology sector, is making waves in precision oncology with its innovative approach to targeting RAS-addicted cancers. Headquartered in Redwood City, California,..

Exelixis, Inc. (EXEL) Stock Analysis: A Healthcare Giant with a 3.03% Upside Potential

Exelixis, Inc. (NASDAQ: EXEL), a prominent player in the biotechnology sector, has been making waves with its innovative contributions to oncology treatments. Headquartered in Alameda, California, this $11.92 billion market..

Regencell Bioscience Holdings L (RGC) Stock Analysis: What Investors Need to Know About This $15.53 Billion Market Cap Healthcare Innovator

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is capturing the attention of investors with its unique position in the healthcare sector, specifically in the specialized field of Traditional Chinese Medicine (TCM)..

BrightSpring Health Services (BTSG): Analyst Ratings Signal Strong Buy Amid 9.71% Potential Upside

BrightSpring Health Services, Inc. (BTSG), a key player in the U.S. healthcare sector, is capturing investor attention with its robust growth trajectory and favorable analyst ratings. Operating within the Health..

Bio-Techne Corp (TECH) Stock Analysis: Navigating a 2.7% Potential Upside with Strong Buy Ratings

In the dynamic world of biotechnology, Bio-Techne Corp (NASDAQ: TECH) emerges as a compelling investment with a robust market presence and a strategic focus on innovation. Headquartered in Minneapolis, Minnesota,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds